COPART Registry: A real-world study of external applicability of the COMPASS and the VOYAGER-PAD trials in patients with lower extremity artery disease
Latest Information Update: 11 Oct 2021
Price :
$35 *
At a glance
- Drugs Aspirin (Primary) ; Rivaroxaban (Primary)
- Indications Cardiovascular disorders; Coronary artery disease; Myocardial infarction; Stroke
- Focus Adverse reactions; Therapeutic Use
- 11 Oct 2021 New trial record
- 01 Sep 2021 Results published in the European Journal of Vascular and Endovascular Surgery